Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Size: px
Start display at page:

Download "Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D"

Transcription

1 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology & Biomedical Association April 15, 2014

2 Trend in R&D Efficiency Number of Drugs per Billion US$ R&D Spending Source: Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington, Diagnosing the decline in pharmaceutical R&D efficiency, Nature Reviews Drug Discovery 11, (March 2012) 2014 Eli Lilly and Company 2

3 $ billion NIH Program Level in Nominal Dollars and Constant 1998 Dollars Appropriation Appropriation in 1998 Dollars *Post-sequester **President s Budget Source: National Institutes of Health 2014 Eli Lilly and Company 3

4 Pharmaceutical Industry Consolidation Mergers have reduced the industry to a few major players DATES DEALS WERE ANNOUNCED Lilly 135 Pfizer Glaxo-Smith Kline Sanofi-Aventis Squibb Bristol-Myers Novartis Astra-Zeneca Genentech (Roc he ha s held a ma jority sta ke sinc e 1990 a nd fully a c q uired in 2009.) Bristol-Myers Squibb Bristol-Myers Squibb Lilly Merck Roche Independent centers of innovation are declining Mergers have been a significant disruptive force on the industry Lilly is unique among the major pharma The New York Times. Sources: Credit Suisse; company reports; Bloomberg 2014 Eli Lilly and Company 4

5 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

6 Science Has Made Dramatic Advances Decline in the cost of sequencing a human genome Logarithmic Scale $100,000,000 Cost per Genome $10,000,000 $1,000,000 $100,000 $10,000 The cost per genome has declined from $95,000,000 in Sept to $5,000 in Oct $1,000 Jan-01 Jan-02 Jan-03 Jan-04 Jan-05 Jan-06 Jan-07 Jan-08 Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 Jan-14 Source: NIH, National Human Genome Research Institute 2014 Eli Lilly and Company 6

7 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

8 External Innovation Ecosystem Internal Innovation Ecosystem Building Sustainable R&D at Lilly Boosting internal efforts with access to external innovation Assets Technologies Capabilities Public-Private Partnerships Licensing Ventures Open Innovation Risk Share Academia Merger & Acquisition Integration Discovery Phase I Phase II Phase III Lilly Pipeline Eli Lilly and Company 8

9 Open Innovation Drug Discovery Year-end Affiliations in 34 Countries University Small Biotech 2014 Eli Lilly and Company 9

10 Project-Focused Companies (PFCs) Lilly Contributions: Capital Compounds Capabilities Lilly & Other Investors VC General Partner Candidates licensed from Lilly or 3 rd Party > $250 M in funds for up to 25 PFCs POCs sold to Lilly or 3 rd Party LLY PFC LLY PFC LLY PFC 3 rd Party PFC 3 rd Party PFC 3 rd Party PFC Chorus Other Engines 2014 Eli Lilly and Company 10

11 New Vehicles to Access and Advance Clinical-Stage Molecules Model/Company Therapeutic Area Investors Origin of Asset PFC: Arteaus Migraine Atlas Venture OrbiMed Advisors Lilly PFC: Tensha Oncology HealthCare Ventures Academia PFC: Dekkun Oncology HealthCare Ventures Lilly PFC: Anexon CV HealthCare Ventures Academia PFC: Kaneq Diabetes TVM Pharma PFC: Ixchelsis Men s Health TVM Pharma PFC: GITR Oncology HealthCare Ventures Biotech PFC: Apofore Diabetes HealthCare Ventures Academia PFC: GLWL Research Diabetes TVM Lilly Option: Transition Therapeutics OA Pain Lilly Option: Transition Therapeutics Diabetes Lilly PFC = Project-Focused Company 2014 Eli Lilly and Company 11

12 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

13 Lilly R&D Network Discovery Phase I Phase II Phase III Lilly Pipeline Internal Research Functional Outsourcing Corporate Venture Capital Early Stage Funds Public Private Partnerships Consortia Collaborations Academic Hubs In-licensing Open Innovation (OIDD) Internal Research & Development Functional Outsourcing Capital Funds (Project Focused Companies) Corporate Venture Capital Public Private Partnerships Consortia Co-Development In-licensing Chorus Internal Development Functional Outsourcing Public Private Partnerships Consortia Strategic Alliances Co-Development In-licensing 2014 Eli Lilly and Company 13

14 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

State of Licensing 2011 Update

State of Licensing 2011 Update State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-

More information

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Life Sciences Outlook

Life Sciences Outlook New Jersey 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 New Jersey The pharmaceutical/life sciences industry has historically been one of New Jersey

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

Life Sciences Outlook. New York City 2016

Life Sciences Outlook. New York City 2016 Life Sciences Outlook City 2016 City is emerging as a leading destination for biotech startups and the larger life sciences industry. Investors have committed millions of dollars throughout the city and

More information

TRANSLATIONAL SCIENCE

TRANSLATIONAL SCIENCE TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM

More information

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members

More information

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager

More information

Transforming the right molecules into the best medicines TM

Transforming the right molecules into the best medicines TM August 2017 Transforming the right molecules into the best medicines TM We are passionate in our mission to improve the health of patients by providing novel strategic alternatives to companies wishing

More information

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011 Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID

More information

Growing the pipeline, growing the bottom line. Shifts in pharmaceutical R&D innovation. kpmg.com KPMG INTERNATIONAL

Growing the pipeline, growing the bottom line. Shifts in pharmaceutical R&D innovation. kpmg.com KPMG INTERNATIONAL Growing the pipeline, growing the bottom line Shifts in pharmaceutical R&D innovation kpmg.com KPMG INTERNATIONAL CONTENTS Page 4 The great research challenge Page 8 Organizational barriers to innovation

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research Life Sciences New Jersey 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research 2 New Jersey Over the course of the past 130 years, the pharmaceutical/life sciences

More information

Innovating 4 DSM

Innovating 4 DSM Innovating 4 Change @ DSM Lessons from 1995 ~ 2015 Rob Kirschbaum, CEO SakuragiConsult (former VP Open Innovation DSM) Micro MBA, Breukelen, October, 2017 Introduction to Royal DSM Strategy; Emerging Business

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009 The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of

More information

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited

More information

PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018

PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018 PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 The increase in deal activity in Q 18 sets the stage for a strong second half of the year. Companies continue to review their portfolios for

More information

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and

More information

PANEL DISCUSSION & ROUNDTABLES

PANEL DISCUSSION & ROUNDTABLES LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the

More information

Biotech Concerto #6 Investment Process December 2008

Biotech Concerto #6 Investment Process December 2008 Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision

More information

A Vision for Health Research and Innovation in Canada

A Vision for Health Research and Innovation in Canada A Vision for Health Research and Innovation in Canada Natalie Dakers President and CEO. Transforming Opportunity into Value 1 The Return on Public Investments in Research Have Not Been Maximized Net Royalty

More information

Strong Equity Support

Strong Equity Support Strong Equity Support Avista team has an intimate i knowledge of the offshore drilling business Avista s Co-Managing Partner, Steve Webster, founded Falcon Drilling and served at its CEO and R&B Falcon

More information

Innovation and the Changing Practice of Medicine

Innovation and the Changing Practice of Medicine Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is

More information

The 2011 EU industrial R&D investment SCOREBOARD

The 2011 EU industrial R&D investment SCOREBOARD 1 The 2011 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández Alex Tuebke Fernando Hervás 1. Background 2 Understanding the dynamics of industrial R&D at

More information

Utrecht Region. At the heart of the Netherlands Life Sciences and Health industry. Why locate your life sciences company in the Utrecht Region?

Utrecht Region. At the heart of the Netherlands Life Sciences and Health industry. Why locate your life sciences company in the Utrecht Region? Utrecht Region At the heart of the Netherlands Life Sciences and Health industry Why locate your life sciences company in the Utrecht Region? Utrecht is at the heart of the Netherlands life sciences industry

More information

European companies outpace American counterparts in R&D investment growth for the first time in five years

European companies outpace American counterparts in R&D investment growth for the first time in five years IP/08/1504 Brussels, 15 October 2008 European companies outpace American counterparts in R&D investment growth for the first time in five years R&D investment by EU companies has increased by 8.8% compared

More information

Utrecht Region. A key role in the Netherlands medical technology industry. Why locate your medical technology company in the Utrecht Region?

Utrecht Region. A key role in the Netherlands medical technology industry. Why locate your medical technology company in the Utrecht Region? Utrecht Region A key role in the Netherlands medical technology industry Why locate your medical technology company in the Utrecht Region? The medical technology focus within the region s life sciences

More information

Early Valuation. Company Portfolio

Early Valuation. Company Portfolio Early Valuation Company Portfolio The current strategy Idea PoC Regulatory Clinical Development Basic Science / Experts Operations Marketing / KOL Commercial Health Innovation Technology Transfer 1 I d

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT. Executive Committee Guido Oelkers Chief Executive Officer Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London,

More information

Ownership/ Partnership/ Principal. None None None Lantheus Medical Imaging (DSMB) NIH (DSMB)* None None None None None None

Ownership/ Partnership/ Principal. None None None Lantheus Medical Imaging (DSMB) NIH (DSMB)* None None None None None None AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (Comprehensive) ACCF/AHA 2013 GUIDELINE FOR THE MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION (October, 2012) Committee Member Patrick T. O Gara,

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Research Patents in Biotech SMEs

Research Patents in Biotech SMEs Research Patents in Biotech SMEs Doorways, Obstacles, Fortifications & Bridges Neil Thomas PhD Director of Intellectual Property, Genetrix Group, Madrid, Spain. Agenda 1. Introduction to Genetrix Definition

More information

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for

More information

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Triton Technology Fund

Triton Technology Fund Triton Technology Fund Presentation to Dean s Engineering Council March 22, 2013 Generate Returns for LPs/GPs Motivation for Fund Catalyze translation of UCSD discoveries for the benefit of society Enable

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

Report of the DTL Partner Advisory Committee meeting November 23 rd 2017, h

Report of the DTL Partner Advisory Committee meeting November 23 rd 2017, h Report of the DTL Partner Advisory Committee meeting November 23 rd 2017, 14.00-17.00 h Meeting location: DTL, Jaarbeurs Innovation Mile, Jaarbeursplein 6, 3521 AL Utrecht Attendees: Formal representatives

More information

Crack the Code: Demystify the Success Factors for Career Development

Crack the Code: Demystify the Success Factors for Career Development Crack the Code: Demystify the Success Factors for Career Development March 1, 2014, Saturday Rutgers University 675 Hoes Lane West Piscataway, NJ 08854 Sino-American Pharmaceutical Professionals Association

More information

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table.

More information

European Trends in Healthcare Investments and Exits 2018

European Trends in Healthcare Investments and Exits 2018 European Trends in Healthcare Investments and Exits 2018 ANNUAL REPORT 2018 Nooman Haque Managing Director Life Science & Healthcare Bobby Anderson Senior Associate Life Science & Healthcare Vojtech Trebicky

More information

Funding New Innovations

Funding New Innovations Funding New Innovations Dr Belinda Clarke Lead Technologist, Biosciences (Synthetic Biology) email: belinda.clarke@tsb.gov.uk twitter: @Belinda_Clarke What is the problem we are addressing? Business investment

More information

Lycera Corporation. Summary. Operating Partner (October 2016 Present)

Lycera Corporation. Summary. Operating Partner (October 2016 Present) PAUL JAI SEKHRI Summary 30 years of deep operational experience in life sciences including general management, corporate and business strategy, technology identification and drug development, business

More information

FDA Centers of Excellence in Regulatory and Information Sciences

FDA Centers of Excellence in Regulatory and Information Sciences FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

Presentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners

Presentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners CHINA GLOBAL CHINA Presentation to Medicon Valley Alliance Crescendo Conference Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners October 2013 0 We are an Ally and a Bridge. We are

More information

Course Goals/Objectives. The course has five objectives:

Course Goals/Objectives. The course has five objectives: NYU Langone Medical Center Postdoctoral Program and the Sackler Institute for Graduate Biomedical Sciences Fundamentals of Technology Commercialization Course Leader: Dr. Sadhana Chitale Class meets Wednesdays,

More information

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the

More information

The partner of choice for self-care products

The partner of choice for self-care products The partner of choice for self-care products Venture Life Group plc Full Year Results Presentation 2017 22 March 2018 2017 highlights Revenues up 12% to 16.1m (2016: 14.3m) Gross profit increased 18% to

More information

CDMO Partnering Strategies for Managing a Broad Portfolio of Molecules: A Novel Biopharma s Approach. AAPS Workshop November 12 th 2017

CDMO Partnering Strategies for Managing a Broad Portfolio of Molecules: A Novel Biopharma s Approach. AAPS Workshop November 12 th 2017 CDMO Partnering Strategies for Managing a Broad Portfolio of Molecules: A Novel Biopharma s Approach AAPS Workshop November 12 th 2017 Transforming the right molecules into the best medicines TM We are

More information

GOALS FOR PRESENTATION

GOALS FOR PRESENTATION Shubha Ghosh Professor of Law Associate Director, INSITE University of Wisconsin, Madison GOALS FOR PRESENTATION Background Major Issues Policy Concerns 2 My Background PhD in Economics from Michigan and

More information

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary

More information

Are Biotechnology Startups Different?

Are Biotechnology Startups Different? Are Biotechnology Startups Different? Hervé Lebret Ecole Polytechnique Fédérale de Lausanne Vice-Presidency for Innovation, CH-1015 Lausanne, Switzerland Email: herve.lebret@epfl.ch Phone: +41 21 693 70

More information

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences

More information

International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs

International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs Do you want to strengthen your business plan for your company?, or refresh your

More information

9 Vaccine SMEs' Needs

9 Vaccine SMEs' Needs 9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor

More information

Launch of new transatlantic specialty pharma company

Launch of new transatlantic specialty pharma company For immediate release Thursday 1 March 2007 EUSA Pharma Inc ( EUSA Pharma or the Company ) Launch of new transatlantic specialty pharma company EUSA Pharma raises $175m for both the acquisition of OPi

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

Digital Health Startups A FirstWord ExpertViews Dossier Report

Digital Health Startups A FirstWord ExpertViews Dossier Report AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in

More information

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research

More information

Industry Advisory Board Harper Cancer Research Institute

Industry Advisory Board Harper Cancer Research Institute Industry Advisory Board Harper Cancer Research Institute Gaylene Anderson, M.B.A. US Director Contracts and Alliance Management Boehringer Ingelheim Pharmaceuticals Gaylene is the US Director of Contracts

More information

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics 1 Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics Eric Dobmeier Chief Business Officer Life science startups are the only companies that are forced to define their

More information

VentureSource Europe -- 3Q 2014

VentureSource Europe -- 3Q 2014 Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a

More information

executives are often viewed to better understand the merits of scientific over commercial solutions.

executives are often viewed to better understand the merits of scientific over commercial solutions. Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for

More information

Health & Social Care Industrial Innovation

Health & Social Care Industrial Innovation Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging

More information

Digital Health, Technology and Life Sciences. Skip Fleshman

Digital Health, Technology and Life Sciences. Skip Fleshman Digital Health, Technology and Life Sciences Skip Fleshman General Partner skip@assetman.com @SkipFleshman, @AMV Firm Facts AMV invests in early stage startups spanning digital health, technology and life

More information

Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co.

Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Risk taking: the key to securities law

More information

Igor Fisch. New candidate, independent

Igor Fisch. New candidate, independent Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Management Team. Bruce C. Cozadd Chairman and Chief Executive Officer

Management Team. Bruce C. Cozadd Chairman and Chief Executive Officer Bruce C. Cozadd Chairman and Chief Executive Officer Bruce Cozadd joined Jazz Pharmaceuticals at its inception and was appointed Jazz Pharmaceuticals Chief Executive Officer in April 2009. From 2003 until

More information

Science - Industry Relationships in High-tech Sectors: Transatlantic Perspectives

Science - Industry Relationships in High-tech Sectors: Transatlantic Perspectives Science - Industry Relationships in High-tech Sectors: Transatlantic Perspectives OECD / BMB+F Conference on Industry - Science Relationships Berlin, October 16-17th, 2000 no. 1 1. Empirical Basis Higher

More information

The Next Generation: Top 20 Life Science Startups to Watch in 2017

The Next Generation: Top 20 Life Science Startups to Watch in 2017 The Next Generation: Top 20 Life Science Startups to Watch in 2017 1/3/2017 3:19:44 PM January 9, 2017 By Mark Terry, BioSpace.com Breaking News Staff BioSpace (DHX) is proud to present its NextGen Class

More information

Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.

Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew. Reference List Cha, Myoung., and Theresa Lorriman. February 2014. Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew. September 24, 2015. Pharmaceuticals: Value over Volume. Financial

More information

Using Academic Licensing Agreements to Promote Global Social Responsibility

Using Academic Licensing Agreements to Promote Global Social Responsibility Using Academic Licensing Agreements to Promote Global Social Responsibility Equitable Licensing of Medical Research Results Charité - Universitätsmedizin Berlin April 26, 2009 Dr. Ashley J. Stevens Executive

More information

GREATER MONTRÉAL Life Sciences & Health Tech hub

GREATER MONTRÉAL Life Sciences & Health Tech hub GREATER MONTRÉAL Life Sciences & Health Tech hub Christelle Fasano, PharmD Director, Business Development Life Sciences & Health Technologies Foreign Investments 2018 1 01 Life sciences: a strategic sector

More information

Michael P. Ridley, Director. NYSTAR High Performance Computing Program

Michael P. Ridley, Director. NYSTAR High Performance Computing Program NYSTAR High Performance Computing Program Michael P. Ridley, Director NYSTAR High Performance Computing Program David A. Paterson, Governor Edward Reinfurt, Executive Director Outline 1 Program Goals 2

More information

New York City Healthcare Venture Capital Report 2018

New York City Healthcare Venture Capital Report 2018 New York City Healthcare Venture Capital Report 2018 Introduction We are delighted to bring you the first annual New York City Healthcare Venture Capital Report 2018. The goal is to provide entrepreneurs,

More information

BOARD OF DIRECTORS. PETER WEHRLY Chair

BOARD OF DIRECTORS. PETER WEHRLY Chair BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held

More information

Purvi B. Maniar Member of the Firm

Purvi B. Maniar Member of the Firm Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

Florida Venture Capital Highlights

Florida Venture Capital Highlights InternetCoast Florida Innovation Highlights Series Florida Venture Capital Highlights 2013 2017 2017 Florida Investment Activity Best Since 2000 InternetCoast January 2018 Dale Gregory President, InternetCoast

More information

Kate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point

Kate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point Kate Pretty Lecture Thursday 8 March 2018 Pascal Soriot, CEO AstraZeneca What Science Can Do The Cambridge Cluster at a Pivot Point Introduction Thank you for your invitation and warm welcome to Homerton

More information

(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K

(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K DCRI Commercial relationships Tracking Form Year: 2018 Name: Adrian Hernandez, M.D. Title: Vice Dean, Clinical, School of Medicine Address: 200 Trent Dr., Durham NC 27710 Please complete the applicable

More information

56 The Milken Institute Review

56 The Milken Institute Review 56 The Milken Institute Review tk Financing High-Risk Medical Research A Proposal from FasterCures By Melissa Stevens tk First Quarter 2016 57 In the past few years, the media has showered us with headlines

More information

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS INDUSTRY RE FUNDS 1969 to present Industry surveys, quarterly and annual fund reports 9,240+ venture capital and private equity funds Venture capital and buyout funds that have invested in companies Name

More information